Cldn1 Knockout cell line (CHO-K1)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

Clec10a (C-type lectin domain family 10, member A) encodes a predicted pattern-recognition receptor with binding activity for D-mannose and fucose. It may participate in inflammatory responses and wound healing, including connective tissue replacement. The protein is predicted to localize to the external surface of the plasma membrane. Its human ortholog, CLEC10A, belongs to the C-type lectin receptor family.

The CHO-K1 cell line was derived as a distinct karyotypic subclone from the parental CHO cell line, which was originally initiated by T. T. Puck in 1957 from an ovary biopsy of an adult Chinese hamster. Due to the absence of a critical gene in the proline biosynthetic pathway—specifically blocked at the step converting glutamic acid to glutamine $gamma$ semialdehyde—these cells strictly require exogenous proline supplementation for survival and growth. Additionally, CHO-K1 cells exhibit distinct morphological changes in response to cholera toxin, serving as a premier and robust host model globally utilized for recombinant protein expression, biopharmaceutical manufacturing, and genetic research.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.